143 related articles for article (PubMed ID: 31772296)
1. Revisiting complete response in light chain amyloidosis.
Sidana S; Dispenzieri A; Murray DL; Go RS; Buadi FK; Lacy MQ; Gonsalves WI; Dingli D; Warsame R; Kourelis T; Muchtar E; Hayman SR; Kapoor P; Kyle RA; Leung N; Rajkumar SV; Gertz MA; Kumar SK
Leukemia; 2020 May; 34(5):1472-1475. PubMed ID: 31772296
[No Abstract] [Full Text] [Related]
2. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
[TBL] [Abstract][Full Text] [Related]
6. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
7. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
8. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
Palladini G; Milani P; Basset M; Russo F; Lavatelli F; Nuvolone M; Ferraro G; Bozzola M; Foli A; Perlini S; Merlini G
Amyloid; 2017 Mar; 24(sup1):54-55. PubMed ID: 28434293
[No Abstract] [Full Text] [Related]
9. Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Roussel M; Rannigan L; Gibbs SDj; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD
Haematologica; 2014 Dec; 99(12):e260-3. PubMed ID: 25193959
[No Abstract] [Full Text] [Related]
10. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type.
Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar VS; Gertz MA
Amyloid; 2017 Mar; 24(sup1):44-45. PubMed ID: 28434304
[No Abstract] [Full Text] [Related]
11. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.
Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Dingli D; Ansell SM; Gastineau DA; Inwards DJ; Johnston PB; Litzow MR; Micallef IN; Porrata LF; Leung N; Hogan WJ; Buadi FK
Leuk Lymphoma; 2010 Dec; 51(12):2181-7. PubMed ID: 20958232
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement.
Zhang LL; Shen KN; Zhang CL; Qiu Y; Miao HL; Feng J; Cao XX; Zhang L; Zhou DB; Li J
Leuk Res; 2019 Nov; 86():106226. PubMed ID: 31541941
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors in light chain amyloidosis].
Jávorniczky NR; Bodó I; Masszi T; Mikala G
Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
[TBL] [Abstract][Full Text] [Related]
15. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.
Muchtar E; Dispenzieri A; Leung N; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves W; Kourelis TV; Warsame R; Russell SJ; Lust JA; Lin Y; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Leukemia; 2019 Feb; 33(2):527-531. PubMed ID: 30258095
[No Abstract] [Full Text] [Related]
16. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
[TBL] [Abstract][Full Text] [Related]
17. Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern Era.
Baljevic M
Oncology (Williston Park); 2021 Aug; 35(8):474-475. PubMed ID: 34398595
[TBL] [Abstract][Full Text] [Related]
18. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
19. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.
Browning S; Quillen K; Sloan JM; Doros G; Sarosiek S; Sanchorawala V
Blood; 2017 Sep; 130(11):1383-1386. PubMed ID: 28698204
[No Abstract] [Full Text] [Related]
20. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
